A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non–Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study)

First-line treatment of non–small cell lung cancer (NSCLC) has undergone a paradigm shift to platinum combination chemotherapy together with an immune checkpoint inhibitor, regardless of the expression level of the programmed cell death–1 (PD-1) ligand PD-L1 on tumor cells. Moreover, such chemothera...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical lung cancer 2022-06, Vol.23 (4), p.e285-e288
Hauptverfasser:	Shiraishi, Yoshimasa, Hakozaki, Taiki, Nomura, Shogo, Kataoka, Tomoko, Tanaka, Kentaro, Miura, Satoru, Sekino, Yuta, Ando, Masahiko, Horinouchi, Hidehito, Ohe, Yuichiro, Okamoto, Isamu
Format:	Artikel
Sprache:	eng
Schlagworte:	CTLA-4 Immune checkpoint inhibitor Overall survival PD-1 Superiority
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!